What we do

Our Research

Our primary project is a next generation topical treatment of eczema (atopic dermatitis) for mild to moderate symptoms

​Non-invasive and easy application

Administered topically via a water based cream. Can easily be administered by the patients themselves

Senior Care

Reduces itch and regenerates tissue

Dampened T-helper responses and onset of cells to target area both reduces sensations of itch and supports the regeneration of the damaged tissue, thus reversing the vicious cycle of itching and worsening AD symptoms.

Senior Care

Intermittent effect

Does not completely depress the immune system, but insteads acts through temporarily inhibiting mast cell degranulation, dendritic cell activation, in addition to stimulating IL-10 production. Hence, the immune system is directed towards immune regulation and not blunt immunesupression. This allows for continued symptom inhibition beyond the treatment period.

Senior Care
ABOUT US

Founded by Prof. Anna-Lena Spetz, our journey began with the serendipitous discovery of the single-stranded oligonucleotide that we call TIR-01, a remarkable compound with profound immunomodulatory properties. Today, TIRmed stands at the forefront of new innovations within topical treatments, shaping the future treatments for  inflammatory skin diseases.

Prof. Anna-Lena Spetz

Founder, Chief Scientific Officer

"There is a large unmet need for effective, non-steroid topical treatments for patients suffering from mild-moderate eczema, especially for children and young adults. TIRmed´s immunoregulatory cream has the potential to fill this gap"

OUR team

Management

With years of experience in the senior care industry, our compassionate team of caregivers and professionals is committed to delivering personalized care tailored to the specific requirements.

Leo Holmgren
CEO

Former consultant at BCG. Strategy specialist, with experiences as advisor for multiple pharma deals and large strategic projects. Previously engaged in raising capital in SME settings. Masters from London Business School.

Prof. Anna-Lena Spetz
CSO, Founder

30 years in immunology research with previous roles at Karolinska Institutet, Institut Pasteur, and Dana-Farber Cancer Institute, Harvard Medical School.

Dr. Pirkko Tamsen
Clinical Development & Regulatory Lead

30 years of experience in the pharmaceutical industry, including clinical trials and regulatory work.Leadership roles at Astra and Kabi aswell as CEO of a CRO and several pharmaceutical and life science SMEs(listed and private).

Assoc. Prof. Jan-Erik Nyström
IP & Business Strategy

Over 30 years of experience at Astra Zeneca in senior leadership roles, including Director of Chemistry and Project Leader in the CNS and Pain Control therapeutic areas. Expertise in drug discovery, intellectual property strategy, and clinical development.

Latest News

Senior Care
News
Successful results in subcutaneous repeated dose study in rats

TIRmed successfully completes key toxicity study

November 8, 2023

Senior Care
News
TIRmed's Recent Dermal Study Yields Promising Results

In a recent development, TIRmed has conducted a biodistribution study that has yielded very promising results. The study, focused on dermal applications, marks a significant milestone in the company's ongoing research efforts.

November 8, 2023

Senior Care
News
Pirkko Tamsen new member of its Board of Directors

TIRmed Pharma is pleased to announce the appointment of Pirkko Tamsen as a new member of its Board of Directors.

November 8, 2023